Valutek Donation Supports TGen's Genomic Research and Discovery Programs
News Dec 10, 2007
Valutek has made a $10,000 product donation to the Translational Genomics Research Institute (TGen). The contribution actively supports Phoenix's burgeoning biotech movement and directly benefits TGen's research initiatives.
"Valutek has a huge customer base in the biotech industry, and we're thrilled to support an organization that does such noble and exciting work," said Greg Heiland, CEO and President of Valutek.
"TGen is on the cutting edge of translational genomics research, and will continue to buoy the emerging biotechnology movement here in Phoenix. We will, in turn, provide products and services to TGen that will fuel this growth," Heiland continued.
In-kind donations are a valuable resource for TGen. Gifts like the contribution from Valutek help fund TGen's research, which is focused on developing earlier diagnoses and smarter treatments for many human diseases, including cancer, diabetes and neurological disorders.
According to TGen Foundation President Michael Bassoff, "Valutek's contribution is a meaningful donation that directly and immediately benefits our researchers. TGen is delighted to partner with Valutek and we look forward to working with Valutek in our ongoing research efforts."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.